三谷 誠一郎 (ミタニ セイイチロウ)

  • 医学科 医学部講師
Last Updated :2024/04/23

コミュニケーション情報 byコメンテータガイド

  • コメント

    エビデンスに基づいた治療の実践だけでなく、治療や臨床試験など新たな治療開発にも積極的に携わっています。

研究者情報

学位

  • 医学部博士(2023年04月 近畿大学)

ホームページURL

J-Global ID

現在の研究分野(キーワード)

    エビデンスに基づいた治療の実践だけでなく、治療や臨床試験など新たな治療開発にも積極的に携わっています。

研究活動情報

論文

  • Seiichiro Mitani; Yosuke Kito; Kaori Hino; Kentaro Kawakami; Naoki Izawa; Fumiyasu Hanamura; Yoshiyuki Yamamoto; Hirokazu Shoji; Azusa Komori; Shogen Boku; Kenji Tsuchihashi; Kyoko Kato; Yoshikane Nonagase; Toshihiko Matsumoto; Mitsuhiro Furuta; Hisato Kawakami
    Targeted oncology 18 5 707 - 715 2023年09月 
    BACKGROUND: Data regarding treatment sequence for vulnerable patients with metastatic colorectal cancer (mCRC) in a real-world setting are lacking. OBJECTIVE: We aimed to assess treatment outcomes in second-line or later chemotherapy for vulnerable patients with mCRC in a real-world setting. PATIENTS AND METHODS: Vulnerable patients with mCRC who received less intensive treatment ('vulnerable') regimens, i.e. fluoropyrimidines with or without biologics (FP), reduced-dose doublet regimens with or without biologics (Doublet), and anti-epidermal growth factor receptor monotherapy (Anti-EGFR), as first-line therapy between June 2015 and December 2018 were retrospectively reviewed. RESULTS: A total of 210 patients from 15 hospitals were analyzed. The median age was 78 years (range 28-90), and 44 patients (21%) had an Eastern Cooperative Oncology Group performance status (ECOG PS) score of 2. In the entire population, the median time to treatment failure (TTF) and overall survival (OS) were 7.6 and 21.4 months, respectively. Following the failure of first-line therapy in 195 patients, 74 (38%), 24 (12%), and 13 (7%) patients received vulnerable regimens, full-dose doublet regimens with or without biologics, and other regimens, respectively, whereas 84 (43%) received best supportive care (BSC). In patients receiving vulnerable regimens as second-line therapy, the median TTF and OS were 4.4 and 13.7 months, respectively, while response rate and disease control rate were 18% and 62%, respectively. In 84 patients who received BSC, the median OS was 3.5 months. CONCLUSIONS: Second-line chemotherapy for vulnerable patients with mCRC showed clinically meaningful outcomes; however, few patients received second-line therapy, and survival among patients who received BSC was dismal.
  • Ryosuke Kumanishi; Shigenori Kadowaki; Seiichiro Mitani; Tomohiro Matsushima; Takatsugu Ogata; Yukiya Narita; Toshiki Masuishi; Hideaki Bando; Masahiro Tajika; Hisateru Yasui; Hiroki Hara; Kei Muro
    International journal of clinical oncology 28 6 756 - 763 2023年06月 
    BACKGROUND: The present study aimed to compare the efficacy and safety of nivolumab (NIVO) and irinotecan (IRI) and to identify clinical factors that facilitate treatment selection. METHODS: Patients with advanced gastric cancer (AGC) who underwent NIVO or IRI treatment between November 2016 and June 2018 at three institutions were retrospectively reviewed. The inclusion criteria were histologically confirmed gastric/gastroesophageal adenocarcinoma pretreated with fluoropyrimidines and taxanes, no previous NIVO or IRI treatment, and adequate organ function. Main outcome measures were objective response rate (ORR), progression-free survival (PFS), overall survival (OS), and adverse events. Interaction between treatment groups and clinical factors regarding OS were tested using a multivariate Cox proportional hazards model adjusted for relevant variables. RESULTS: Both NIVO (n = 71) and IRI (n = 61) groups had similar baseline characteristics, except for sex distribution. NIVO and IRI groups had ORR of 20% and 6%, median PFS of 1.6 and 1.8 months, and median OS of 6.4 and 6.4 months, respectively. Interaction analysis did not reveal any significant interaction between NIVO and IRI related to OS for various factors. NIVO group tended to have fewer ≥ grade 3 adverse events than IRI group, especially neutropenia (3% vs. 28%) and febrile neutropenia (1% vs. 8%). In the NIVO group, one patient developed pneumonitis, and four patients developed skin reactions. CONCLUSIONS: Although no remarkable differences in efficacy were found between IRI and NIVO for AGC, NIVO had a better safety profile compared to IRI. We found no clinical markers that can assist treatment decisions.
  • Seiichiro Mitani; Hisato Kawakami; Osamu Shiraishi; Hiroaki Kanemura; Shinichiro Suzuki; Koji Haratani; Hidetoshi Hayashi; Kimio Yonesaka; Yasutaka Chiba; Takushi Yasuda; Kazuhiko Nakagawa
    Esophagus : official journal of the Japan Esophageal Society 20 2 290 - 290 2023年01月
  • Takashi Kurosaki; Kenji Chamoto; Shinichiro Suzuki; Hiroaki Kanemura; Seiichiro Mitani; Kaoru Tanaka; Hisato Kawakami; Yo Kishimoto; Yasuharu Haku; Katsuhiro Ito; Toshiyuki Sato; Chihiro Suminaka; Mami Yamaki; Yasutaka Chiba; Tomonori Yaguchi; Koichi Omori; Takashi Kobayashi; Kazuhiko Nakagawa; Tasuku Honjo; Hidetoshi Hayashi
    Frontiers in immunology 14 1325462 - 1325462 2023年 
    INTRODUCTION: The clinical relevance of soluble forms of programmed cell death-1 (sPD-1) and programmed cell death-ligand 1 (sPD-L1) remains unclear. We here investigated the relation between the efficacy of PD-1 blockade and pretreatment plasma levels of sPD-1 and sPD-L1 across a broad range of cancer types. METHODS: We retrospectively analyzed clinical data from 171 patients with advanced solid tumors who received nivolumab or pembrolizumab monotherapy regardless of treatment line. The concentrations of sPD-1 and sPD-L1 were measured with a fully automated immunoassay (HISCL system). RESULTS: The study subjects comprised patients with head and neck cancer (n = 50), urothelial cancer (n = 42), renal cell cancer (n = 37), gastric cancer (n = 20), esophageal cancer (n = 10), malignant pleural mesothelioma (n = 6), or microsatellite instability-high tumors (n = 6). High or low levels of sPD-1 or sPD-L1 were not significantly associated with progression-free survival (PFS) or overall survival (OS) for PD-1 blockade in the entire study population. Comparison of treatment outcomes according to combinations of high or low sPD-1 and sPD-L1 levels, however, revealed that patients with low sPD-1 and high sPD-L1 concentrations had a significantly poorer PFS (HR of 1.79 [95% CI, 1.13-2.83], p = 0.01) and a tendency toward poorer OS (HR of 1.70 [95% CI, 0.99-2.91], p = 0.05) compared with all other patients. CONCLUSION: Our findings suggest that the combination of low sPD-1 and high sPD-L1 levels is a potential negative biomarker for PD-1 blockade therapy.
  • Seiichiro Mitani; Hisato Kawakami; Osamu Shiraishi; Hiroaki Kanemura; Shinichiro Suzuki; Koji Haratani; Hidetoshi Hayashi; Kimio Yonesaka; Yasutaka Chiba; Takushi Yasuda; Kazuhiko Nakagawa
    Esophagus : official journal of the Japan Esophageal Society 20 2 281 - 289 2022年12月 
    BACKGROUND: Neoadjuvant docetaxel plus cisplatin and 5-FU (NAC-DCF) and adjuvant nivolumab monotherapy are the standard care for locally advanced resectable esophageal squamous cell carcinoma (ESCC). However, no effective biomarkers have been found in perioperative setting. We investigated how programmed death-ligand 1 (PD-L1) changes before and after NAC-DCF and how it relates to the therapeutic effect of NAC-DCF in resectable ESCC. METHODS: PD-L1 expression in paired diagnostic biopsy and surgically resected tissues from ESCC patients who underwent surgical resection after receiving two or three NAC-DCF cycles was evaluated. PD-L1 positivity was defined as a combined positive score (CPS) of 10% ≤ . Gene expression analysis was conducted using samples before NAC-DCF. RESULTS: Sixty-six paired samples from 33 patients were included in PD-L1 expression analysis, and 33 Pre-NAC samples acquired by diagnostic biopsy were included in gene expression analysis. Pretreatment, 3 (9%), 13 (39%), and 17 (52%) patients harbored tumors with CPS ranges of < 1%, 1%-10%, and 10% ≤ , respectively. After NAC-DCF, 5 (15%), 15 (45%), and 13 (39%) tumors presented CPS ranges of < 1%, 1%-10%, and 10% ≤ , respectively. The concordance rate between Pre-and Post-NAC-DCF samples was 45%. Patients with PD-L1-negative tumors both before and after NAC-DCF (n = 9) had shorter survival and different gene expression profile characterized by upregulation in WNT signaling or neutrophils. CONCLUSIONS: A substantial PD-L1 expression alteration was observed, resulting in low concordance rate before and after NAC-DCF. Tumors persistently lacking PD-L1 had distinct gene expression profile with worse clinical outcomes, raising the need for further investigation.
  • Shogen Boku; Hironaga Satake; Takashi Ohta; Seiichiro Mitani; Kentaro Kawakami; Yozo Suzuki; Toshihiko Matsumoto; Tetsuji Terazawa; Eiki Yamazaki; Hiroko Hasegawa; Tatsuki Ikoma; Mamoru Uemura; Toshifumi Yamaguchi; Atsushi Naito; Yasunobu Ishizuka; Yukinori Kurokawa; Daisuke Sakai; Hisato Kawakami; Toshio Shimokawa; Toshimasa Tsujinaka; Takeshi Kato; Taroh Satoh; Yoshinori Kagawa
    Future oncology (London, England) 2022年12月 
    The BRAF V600E mutation accounts for approximately 5% of colorectal cancer (CRC) cases and is an extremely poor prognostic factor. However, there are no clear recommendations regarding first-line therapy for patients with early recurrent BRAF V600E-mutated CRC, during or after adjuvant chemotherapy. Recently, a novel combination of encorafenib, binimetinib and cetuximab, showed a higher response rate than standard chemotherapy in patients with BRAF V600E-mutated CRC. Here we describe our plan for the TRESBIEN study (OGSG 2101), which is an open-label, multicenter, single-arm, phase II study designed to evaluate whether encorafenib, binimetinib and cetuximab are effective for patients with early recurrent BRAF V600E-mutated colorectal cancer, during or after adjuvant chemotherapy. The planned number of subjects is 25.
  • Masaki Okura; Seiichiro Mitani
    Gan to kagaku ryoho. Cancer & chemotherapy 49 11 1216 - 1220 2022年11月
  • がん遺伝子パネル検査FoundationOneによる肺癌の遺伝子変異の測定
    米阪 仁雄; 高濱 隆幸; 黒崎 隆; 川中 雄介; 金村 宙昌; 磯本 晃佑; 鈴木 慎一郎; 三谷 誠一郎; 中川 和彦; 白石 直樹; 小田 いつき; 西郷 和真; 池川 敦子; 福岡 和也; 武田 真幸; 西尾 和人
    肺癌 62 5 439 - 439 (NPO)日本肺癌学会 2022年10月
  • がん遺伝子パネル検査FoundationOneによる肺癌の遺伝子変異の測定
    米阪 仁雄; 高濱 隆幸; 黒崎 隆; 川中 雄介; 金村 宙昌; 磯本 晃佑; 鈴木 慎一郎; 三谷 誠一郎; 中川 和彦; 白石 直樹; 小田 いつき; 西郷 和真; 池川 敦子; 福岡 和也; 武田 真幸; 西尾 和人
    肺癌 62 5 439 - 439 (NPO)日本肺癌学会 2022年10月
  • Kaori Hino; Tomohiro Nishina; Takeshi Kajiwara; Hideaki Bando; Maho Nakamura; Shigenori Kadowaki; Keiko Minashi; Satoshi Yuki; Takashi Ohta; Hiroki Hara; Takuro Mizukami; Toshikazu Moriwaki; Koushiro Ohtsubo; Masato Komoda; Seiichiro Mitani; Fumio Nagashima; Ken Kato; Takanobu Yamada; Hiroko Hasegawa; Kentaro Yamazaki; Takayuki Yoshino; Ichinosuke Hyodo
    JCO precision oncology 6 e2200135  2022年08月 
    PURPOSE: ERBB2 copy number (CN), measured using next-generation sequencing, is a predictive biomarker for trastuzumab efficacy in human epidermal growth factor receptor 2 (HER2)-positive advanced esophagogastric and gastric cancer (AGC). We aimed to investigate the association of ERBB2 amplification and gene coalterations with response and resistance to trastuzumab-combined chemotherapy. METHODS: The SCRUM-Japan GI-SCREEN was a comprehensive genomic profiling project of GI cancer tissues using Oncomine Cancer Research Panel and Oncomine Comprehensive Assay. From 885 patients with AGC who successfully underwent gene profiling, 74 with ERBB2 amplification (CN ≥ 4.0) and who received first-line trastuzumab-combined chemotherapy were selected, and ERBB2 CN and gene coalterations were assessed. RESULTS: ERBB2 CN did not differ in tumor response to trastuzumab-combined chemotherapy (one-way analysis of variance test, P = .37). Multivariate analysis using the Cox proportional hazard model revealed that ERBB2 CN (continuous log2-converted CN, hazard ratio, 0.76; 95% CI, 0.62 to 0.93; P < .01) and receptor/oncogene amplifications in the HER2 signaling pathway (hazard ratio, 2.5; 95% CI, 1.2 to 5.3; P = .01) were significant predictors for progression-free survival (PFS). ERBB2 variants coexisted in five patients (7%) and were missense mutations. Two patients with low variant allele frequencies (VAFs; 8%, 12%) showed high ERBB2 CN (55, 80) and durable response (≥ 20 months), whereas three patients with high VAFs (66%-90%) showed low ERBB2 CN (8-11) and no response with short PFS (1-10 months). CONCLUSION: ERBB2 CN and gene coamplification in the HER2 signaling pathway were positive and negative predictors of PFS in trastuzumab-treated HER2-positive AGC patients, respectively. HER2-positive AGC patients with a high VAF of ERBB2 showed poor outcomes and may need HER2 tyrosine kinase inhibitors and trastuzumab deruxtecan.
  • Seiichiro Mitani; Ken Kato; Hiroyuki Daiko; Yoshinori Ito; Isao Nozaki; Takashi Kojima; Masahiko Yano; Satoru Nakagawa; Masaki Ueno; Masaya Watanabe; Shigeru Tsunoda; Tetsuya Abe; Shigenori Kadowaki; Tomohiro Kadota; Keita Sasaki; Ryunosuke Machida; Yuko Kitagawa
    Journal of gastroenterology 57 7 455 - 463 2022年07月 
    BACKGROUND: Previous studies have suggested that patients with esophageal squamous cell carcinoma (ESCC) are still at a high risk of developing second primary malignancies (SPMs) after definitive therapies. We evaluated the development of SPMs and explored its risk factors in patients with clinical T1bN0 ESCC. METHODS: JCOG0502 prospectively compared esophagectomy with definitive chemo-radiotherapy for clinical T1bN0 ESCC. Here, we reviewed all JCOG0502 patients' data for SPMs and investigated the risk factors for SPMs using uni-variable and multivariable analyses by Fine and Gray model. RESULTS: Among 379 enrolled patients, 213 underwent esophagectomy and 166 received chemo-radiotherapy. Patient characteristics were male (85%); median age [63 (range 41-75) years; location of the primary tumor (upper/middle/lower thoracic esophagus, 11%/63%/27%, respectively]; alcohol consumption history (79%); smoking history (66%); prevalence of no/several/many/unknown Lugol-voiding lesions (LVLs) (45%/36%/8%/11%, respectively). In a median follow-up of 7.1 years, 118 SPMs occurred in 99 (26%) patients. Cumulative incidences of SPMs after 3, 5, and 10 years were 9%, 15%, and 36%, respectively. The most common primary tumor sites were the head and neck (35%), stomach (20%) and lungs (14%). In multivariable analyses, compared to no LVLs, several LVLs [hazard ratio (HR) 2.24, 95% confidential interval (CI) 1.32-3.81] and many LVLs (HR 2.88, 95% CI 1.27-6.52) were significantly associated with the development of SPMs. Sixteen patients died due to the SPMs. CONCLUSION: The incidence of SPMs was high. The presence of LVLs, which was a predictive factor for SPMs, may be useful for surveillance planning.
  • Kazuhiko Hashimoto; Shunji Nishimura; Seiichiro Mitani; Tomohiko Ito; Masao Akagi
    Skeletal radiology 2022年03月 
    Myxoid liposarcoma (MLPS) is known to have a variety of metastatic manifestations. We report a MLPS originating in the pelvis with metastasis to the calcaneus. The patient was a 72-year-old man who developed lumbar pain and right lower extremity pain 2 years ago. He visited a nearby clinic and underwent a radiographic examination. Computed tomography (CT) revealed a tumor in the right retroperitoneum. A CT-guided needle biopsy was performed, and pathological examination revealed myxoid liposarcoma. Wide surgical resection was not performed due to the patients' wishes, technical difficulties, and magnitude of the invasion, and the patient received heavy particle radiation therapy (HPRT) of 70.4 Gy. After HPRT, the tumor mass was slightly reduced. However, 11 months after HPRT, a recurrent lesion in the liver was observed. Although HPRT was performed again for the metastatic liver lesion (70.4 Gy), the tumor increased in size. Furthermore, 1 month later, the patient complained of pain in the left foot, and CT and magnetic resonance imaging revealed an osteolytic lesion in the calcaneus. A biopsy was performed, and pathological examination showed a metastatic lesion of myxoid-type liposarcoma. The patient wore a short lower limb orthosis and was able to walk but died 1 month later. Oncologists should note that MLPS can metastasize to the calcaneus.
  • Tomoyuki Otani; Hiroaki Kanemura; Masatomo Kimura; Seiichiro Mitani; Masayuki Takeda; Mitsuru Matsuki; Noriomi Matsumura; Takao Satou; Kazuhiko Nakagawa; Akihiko Ito
    International journal of surgical pathology 30 6 10668969211069963 - 10668969211069963 2022年01月 
    Only four cases of colorectal adenocarcinoma with a yolk sac tumor (YST) component have been reported in the English literature. No genetic investigation has been performed in these cases. We report a case of colorectal adenocarcinoma in which the recurrent tumor had a YST component. A 49-year-old woman presented with a pelvic tumor three years after endoscopic mucosal resection of sigmoid colon adenocarcinoma. The pelvic tumor consisted of an undifferentiated carcinoma component and a YST component. The serum alpha-fetoprotein level was elevated to 42 ng/mL. Treatment as conventional colorectal carcinoma produced some anticancer effects, but the patient died 14 months after the recurrence and 49 months after the EMR. With the help of the next-generation sequencing results of the recurrent tumor, APC c.835 - 8A > G and TP53 c.524G > A (p.R175H) mutations were identified by direct sequencing in both the primary and the recurrent tumors, confirming the relationship between the two metachronous tumors.
  • Akie Kimura Yoshikawa; Kensei Yamaguchi; Kei Muro; Atsuo Takashima; Takashi Ichimura; Daisuke Sakai; Shigenori Kadowaki; Keisho Chin; Toshihiro Kudo; Seiichiro Mitani; Shigehisa Kitano; Dung Thai; Marianna Zavodovskaya; JieJane Liu; Narikazu Boku; Taroh Satoh
    Journal for immunotherapy of cancer 10 1 2022年01月 
    BACKGROUND: Matrix metalloproteinase 9 (MMP9) is implicated in protumorigenic processes. Targeting either stromal or epithelial MMP9 reduces the incidence of metastasis. Andecaliximab is a monoclonal antibody that targets MMP9 with high affinity and selectivity. However, no study has examined whether the inhibition of T-cell programmed death 1 (PD-1) in the presence of andecaliximab increases activated lymphocyte infiltration into the tumor, thereby increasing antitumor activity more than that in anti-PD-1 monotherapy. In this study, we assessed the safety, pharmacokinetics (PK), exploratory biomarkers, and preliminary efficacy of andecaliximab as monotherapy and in combination with nivolumab in Japanese patients with advanced or recurrent gastric or gastroesophageal junction (GEJ) adenocarcinoma. METHODS: This phase 1b study comprised four cohorts enrolling Japanese patients with gastric or GEJ adenocarcinoma. This paper concerns cohorts 1 and 4; cohorts 2 and 3 will be reported subsequently. Cohort 1 enrolled patients with human epidermal growth factor receptor 2 (HER2)-negative tumors (n=8) who received andecaliximab monotherapy (800 mg by intravenous infusion every 2 weeks (Q2W)), and cohort 4 enrolled patients irrespective of their HER2 status (n=10) who received 800 mg of andecaliximab in combination with nivolumab Q2W. Safety, dose-limiting toxicities (DLTs), PK, pharmacodynamics, and biomarkers were assessed in both cohorts. RESULTS: PK of andecaliximab in Japanese patients with gastric or GEJ adenocarcinoma was similar to that reported in non-Japanese patients with advanced solid tumors. Andecaliximab monotherapy and in combination with nivolumab demonstrated no DLTs in cohort 1 and 4, respectively. Toxicities were manageable and well tolerated in both cohorts. The median progression-free survival was 1.4 months (90% CI, 0.5 to 5.4) and 4.6 months (90% CI, 0.9 to not reached) in cohorts 1 and 4, respectively. The objective response rate was 50% (90% CI, 22% to 78%) in cohort 4, and in some patients, the combination therapy was effective regardless of the biomarker status. CONCLUSIONS: The andecaliximab-nivolumab combination demonstrated a manageable safety profile and promising clinical activity in patients with advanced gastric adenocarcinoma.NCT02862535.
  • Shinichiro Suzuki; Koji Haratani; Hidetoshi Hayashi; Yasutaka Chiba; Junko Tanizaki; Ryoji Kato; Seiichiro Mitani; Yusuke Kawanaka; Takashi Kurosaki; Yoshikazu Hasegawa; Takafumi Okabe; Kaoru Tanaka; Yusaku Akashi; Tomohiro Ozaki; Kazuto Nishio; Akihiko Ito; Kazuhiko Nakagawa
    European journal of cancer (Oxford, England : 1990) 161 44 - 54 2022年01月 
    BACKGROUND: Tumour burden (TB) is implicated in resistance to programmed cell death-1/PD-L1 inhibitor (immune checkpoint inhibitor [ICI]) therapy. However, whether TB contributes to such resistance in non-small-cell lung cancer (NSCLC) has remained unknown. METHODS: A total of 260 treatment-naïve patients with advanced NSCLC who started ICI monotherapy (ICI cohort), platinum-doublet therapy (Chemo cohort) or ICI and platinum-doublet therapy (ICI+Chemo cohort) as first-line treatment were consecutively included. TB was estimated on the basis of the sum of the diameters of measurable target lesions as per Response Evaluation Criteria in Solid Tumours. Progression-free survival (PFS) in the ICI cohort was evaluated as per TB as a preplanned primary objective, with the analysis based on propensity score-weighted survival curves and estimation of restricted mean survival time (RMST). The Chemo cohort served as a control to determine whether TB is predictive of ICI treatment outcomes. The ICI+Chemo cohort was exploratory. The relation of TB to tumour immune status was assessed by immune-related gene expression profiling (irGEP) of pretreatment tumour tissue. RESULTS: In the ICI cohort, patients with a low TB showed a significantly longer PFS than did those with a high TB (median, 17.9 vs 4.3 months; weighted hazard ratio, 0.32 [95% confidence interval, 0.19-0.53]). No such difference was apparent in the other cohorts. A significant difference in overall survival was also observed only in the ICI cohort. RMST-based analysis confirmed these results. The irGEP analysis implicated M2-type macrophages, angiogenesis and transforming growth factor-β as well as protumourigenic signalling pathways in ICI resistance conferred by a high TB. CONCLUSION: A high TB was associated with a poor outcome of ICI therapy for advanced NSCLC as a result of immunosuppressive phenotypes. Development of combination or novel treatment strategies for such disease is thus warranted.
  • Shun Yamamoto; Kengo Nagashima; Takeshi Kawakami; Seiichiro Mitani; Masato Komoda; Yasushi Tsuji; Naoki Izawa; Kentaro Kawakami; Yoshiyuki Yamamoto; Akitaka Makiyama; Kentaro Yamazaki; Toshiki Masuishi; Taito Esaki; Takako Eguchi Nakajima; Hiroyuki Okuda; Toshikazu Moriwaki; Narikazu Boku
    BMC Cancer 21 1 2021年12月 
    Abstract Background The ML18174 study, which showed benefits of bevacizumab (BEV) continuation beyond progression (BBP) for metastatic colorectal cancer (mCRC), excluded patients with first-line progression-free survival (PFS) shorter than 3 months. The present study was conducted to evaluate the efficacy of second-line chemotherapy after early disease progression during first-line chemotherapy containing bevacizumab. Methods The subjects of this study were mCRC patients who experienced disease progression < 100 days from commencement of first-line chemotherapy containing BEV initiated between Apr 2007 and Dec 2016. Second-line chemotherapy regimens were classified into two groups with and without BEV/other anti-angiogenic agents (BBP and non-BBP) and efficacy and safety were compared using univariate and multivariate analysis. Results Sixty-one patients were identified as subjects of this study. Baseline characteristics were numerically different between BBP (n = 37) and non-BBP (n = 25) groups, such as performance status (0–1/> 2/unknown: 89/8/3 and 56/40/4%), RAS status (wild/mutant/unknown: 32/54/16 and 76/16/8%). Response rate was 8.6% in BBP group and 9.1% in non-BBP group (p = 1.00). Median PFS was 3.9 months in BBP group and 2.8 months in non-BBP group (HR [95%CI]: 0.79 [0.46–1.34], p = 0.373, adjusted HR: 0.87 [0.41–1.82], p = 0.707). Median overall survival was 8.5 months in BBP group and 5.4 months in non-BBP group (HR 0.66 [0.38–1.12], p = 0.125, adjusted HR 0.53 [0.27–1.07], p = 0.078). Conclusion In mCRC patients who experienced early progression in first-line chemotherapy, second-line chemotherapy showed poor clinical outcomes regardless use of anti-angiogenic agents.
  • Seiichiro Mitani; Yucherng Chen; Koichi Inoue; Joji Mori; Ling Gao; Amanda Long; Satoshi Wakabayashi
    Gan to kagaku ryoho. Cancer & chemotherapy 48 11 1381 - 1387 2021年11月 
    AIM: We evaluated the safety and potential clinical impact of shortened ramucirumab infusion in Japanese patients from clinical studies. METHODS: Multivariate logistic regression analysis was used to assess any association between infusion rate and increased risk of an immediate infusion-related reaction(IRR). Population pharmacokinetic modeling was used to simulate concentration-time profiles and exposure parameters following a 30- or 60-minute infusion with ramucirumab. RESULTS: From 8 pooled ramucirumab clinical studies, 55 of 559(9.8%)Japanese patients experienced at least one immediate IRR(any grade). When grouped according to infusion rate quartile, the incidence of immediate any-grade IRR was similar across quartiles. Infusion rate was not significantly associated with an increased risk of an immediate IRR; odds ratio per 1 mg/min increase was 0.912, 95% confidence interval 0.724 to 1.149, p=0.436. Patients aged ≥65 years may have a reduced risk of an immediate IRR compared with those aged <65 years, and premedication use was also associated with a reduced risk. Ramucirumab pharmacokinetic profiles were comparable following a 30- or 60-minute infusion. CONCLUSIONS: A shortened infusion duration of ramucirumab is unlikely to affect the efficacy or safety profile in Japanese patients and may be clinically beneficial for patients and health care providers. CLINICAL TRIAL REGISTRATION: RAINBOW-NCT01170663, RAISE- NCT01183780, REACH-NCT01140347, REACH-2-NCT02435433, RAINFALL-NCT02314117, RANGE-NCT02426125, RELAY-NCT02411448, I4T-MC-JVCG-NCT01703091.
  • Shigenori Kadowaki; Toshiki Masuishi; Takashi Ura; Keiji Sugiyama; Seiichiro Mitani; Yukiya Narita; Hiroya Taniguchi; Kei Muro
    International journal of clinical oncology 26 4 701 - 707 2021年04月 
    BACKGROUND: The triplet-agent (5-fluorouracil/leucovorin, oxaliplatin, and irinotecan; FOLFOXIRI) combined with an anti-epidermal growth factor receptor antibody as a first-line treatment of metastatic colorectal cancer (mCRC) has shown promising results in Western trials. This phase Ib study assessed the safety of FOLFOXIRI plus cetuximab in Japanese patients with RAS wild-type mCRC. METHODS: Patients with previously untreated RAS wild-type mCRC received weekly cetuximab (400 mg/m2 at week 1 and subsequently 250 mg/m2) plus FOLFOXIRI that consisted of irinotecan (100, 120, and 150 mg/m2 defined as dose levels 0, 1, and 2), followed by oxaliplatin 85 mg/m2 and l-leucovorin 200 mg/m2 and then 5-fluorouracil 2400 mg/m2. The dose level of irinotecan was escalated starting at dose level 1 in a 3 + 3 manner. The primary endpoint was to determine the maximum-tolerated dose (MTD) and the recommended phase-2 dose (RP2D). Secondary endpoints included safety, overall response rate (ORR), progression-free survival (PFS) and overall survival (OS). RESULTS: Nine patients were enrolled. The MTD was not reached at dose level 2 and the RP2D was 150 mg/m2 irinotecan. The most frequent grade 3/4 adverse events were neutropenia (44%), fatigue (11%), paronychia (22%), and acneiform rash (11%). No dose-limiting toxicities occurred in any of the enrolled patients. No treatment-related death was observed. The ORR was 89% (95% confidence interval 52-100%). CONCLUSION: The safety profile of the combination of cetuximab and FOLFOXIRI was acceptable and promising anti-tumor activity was demonstrated, supporting further study in patients with RAS wild-type mCRC.
  • Takashi Kurosaki; Seiichiro Mitani; Kaoru Tanaka; Shinichiro Suzuki; Hiroaki Kanemura; Koji Haratani; Soichi Fumita; Tsutomu Iwasa; Hidetoshi Hayashi; Takeshi Yoshida; Kazuki Ishikawa; Mutsukazu Kitano; Naoki Otsuki; Yasumasa Nishimura; Katsumi Doi; Kazuhiko Nakagawa
    Anti-cancer drugs 32 1 95 - 101 2021年01月 
    Immunotherapy has been shown to prolong survival in recurrent or metastatic squamous cell carcinoma of the head and neck (SCCHN) in front-line use; however, subsequent systemic therapy has not been optimized. This study aimed to evaluate the safety and efficacy of cetuximab-containing chemotherapy after immunotherapy. We retrospectively analyzed patients with recurrent or metastatic SCCHN who underwent cetuximab-containing regimens after progression on immunotherapy. Of the 22 patients who met the inclusion criteria, 21 received paclitaxel and cetuximab, and 1 carboplatin and fluorouracil and cetuximab after immunotherapy. Nine patients achieved a partial response, 10 patients had stable disease as their best response on cetuximab-containing chemotherapy, yielding an overall response rate and disease control rate of 40.9 and 86.4%, respectively. The median progression-free survival was 5.2 months, and the median overall survival was 14.5 months. Ten patients developed grade 3-4 adverse events, including neutropenia (31.8%), acneiform rash (9.1%), anemia (4.5%), hypertransaminasemia (4.5%) and stomatitis (4.5%). The most frequent cetuximab-related toxicities across all grades were skin reactions (77.3%), hypomagnesemia (40.9%), stomatitis (27.3%), paronychia (13.6%) and keratitis (4.5%). There was no treatment-related death. Taken together, cetuximab-containing chemotherapy was effective and feasible even after immunotherapy.
  • Kenta Tsunekuni; Hisato Kawakami; Kazuaki Matsuoka; Hideki Nagase; Seiichiro Mitani; Kazuhiko Nakagawa
    Journal of clinical medicine 9 12 2020年12月 
    Trifluridine/tipiracil (FTD/TPI) (a.k.a. TAS-102) is a combination drug for metastatic colorectal cancer (CRC) and severely pretreated metastatic gastric/gastroesophageal junction (GEJ) cancers, comprising FTD, a thymidine-based antineoplastic nucleoside analog, and TPI, which enhances FTD bioavailability. Herein, in KRAS mutant murine colorectal cancer CT26 syngeneic models, we investigate whether combination therapy with DC101 (a surrogate ramucirumab antibody, rat antimouse vascular endothelial growth factor receptor (VEGFR)-2 monoclonal antibody (mAb)) improves FTD/TPI efficacy. Tumor growth inhibition (TGI) on day 15 was 38.0% and 30.6% upon DC101 monotherapy and FTD/TPI monotherapy respectively, and 60.3% upon combination therapy. Tumor volume was significantly lower (p < 0.001) upon combination treatment than upon FTD/TPI or DC101 monotherapy, indicating the additive effects of FTD/TPI and DC101. DNA-incorporated FTD levels on Day 8 were significantly higher in combination therapy with FTD/TPI (for 5 consecutive days) and DC101 (on alternate days for 7days) than in FTD/TPI monotherapy. Furthermore, vascular endothelial cell-specific marker CD31 was downregulated in DC101-treated tumors on day 8. These results indicate that combination therapy with FTD/TPI and DC101 is a promising treatment alternative regardless of KRAS mutations.
  • Toshiki Masuishi; Hiroya Taniguchi; Azusa Komori; Seiichiro Mitani; Yukiya Narita; Shigenori Kadowaki; Takashi Ura; Masashi Ando; Kei Muro
    The oncologist 25 11 e1614-e1620  2020年11月 
    LESSONS LEARNED: The recommended S-1 dose was 40 mg/m2 , twice daily on Monday, Wednesday, Friday, and Sunday, with oral leucovorin and bevacizumab. Compared with daily administration, the alternate-day administration of S-1 with oral leucovorin may reduce mucositis with promising antitumor activity in refractory metastatic colorectal cancer. BACKGROUND: Daily S-1 plus oral leucovorin administration in a 1-week-on/1-week-off schedule has promising efficacy in gastrointestinal cancer but is associated with high risk of mucositis and diarrhea. METHODS: This phase Ib, 3+3 dose-escalation trial included patients with chemorefractory metastatic colorectal cancer (mCRC) receiving S-1 (40 mg/m2 ) and leucovorin (25 mg) orally twice daily (level 1, even-numbered days; level 2, Monday, Wednesday, Friday, and Sunday) and intravenous bevacizumab (5 mg/kg) every 2 weeks. Enrollment continued at the recommended dose level in the expansion cohort. RESULTS: We enrolled 21 patients (3 and 18 patients in levels 1 and 2, respectively). Briefly, 12 and 9 patients had Eastern Cooperative Oncology Group (ECOG) performance status of 0 and 1, respectively, and 8 and 13 patients had 1-3 and ≥4 prior treatment lines, respectively. Dose-limiting toxicity (DLT) was not observed, and level 2 was confirmed as the recommended dose. Common grade 3-4 adverse events at level 2 were anemia (22%), anorexia (6%), and diarrhea (6%). In the entire cohort, response rate, disease control rate, and median progression-free survival were 10%, 71%, and 4.2 months, respectively. CONCLUSION: The recommended S-1 dose was 40 mg/m2 , twice daily on Monday, Wednesday, Friday, and Sunday, with 25 mg oral leucovorin twice daily and 5 mg/kg bevacizumab every 2 weeks. Compared with the daily administration, alternate-day administration of S-1 plus leucovorin may reduce mucositis with promising antitumor activity in refractory mCRC.
  • 当院での進行頭頸部癌に対するニボルマブの有効性と安全性
    鈴木 慎一郎; 田中 薫; 佐藤 千尋; 金村 宙昌; 磯本 晃佑; 加藤 了資; 原谷 浩司; 三谷 誠一郎; 林 秀敏; 北野 睦三; 石川 一樹; 土井 勝美; 西村 恭昌; 中川 和彦
    頭頸部癌 46 2 151 - 151 (一社)日本頭頸部癌学会 2020年07月
  • 頭頸部癌における免疫チェックポイント阻害薬後のセツキシマブ使用の有効性および安全性
    三谷 誠一郎; 田中 薫; 鈴木 慎一郎; 原谷 浩司; 文田 壮一; 川上 尚人; 吉田 健史; 林 秀敏; 北野 睦三; 土井 勝美; 石川 一樹; 西村 恭昌; 中川 和彦
    頭頸部癌 46 2 218 - 218 (一社)日本頭頸部癌学会 2020年07月
  • 当院での進行頭頸部癌に対するニボルマブの有効性と安全性
    鈴木 慎一郎; 田中 薫; 佐藤 千尋; 金村 宙昌; 磯本 晃佑; 加藤 了資; 原谷 浩司; 三谷 誠一郎; 林 秀敏; 北野 睦三; 石川 一樹; 土井 勝美; 西村 恭昌; 中川 和彦
    頭頸部癌 46 2 151 - 151 (一社)日本頭頸部癌学会 2020年07月
  • 頭頸部癌における免疫チェックポイント阻害薬後のセツキシマブ使用の有効性および安全性
    三谷 誠一郎; 田中 薫; 鈴木 慎一郎; 原谷 浩司; 文田 壮一; 川上 尚人; 吉田 健史; 林 秀敏; 北野 睦三; 土井 勝美; 石川 一樹; 西村 恭昌; 中川 和彦
    頭頸部癌 46 2 218 - 218 (一社)日本頭頸部癌学会 2020年07月
  • Seiichiro Mitani; Shigenori Kadowaki; Azusa Komori; Chihiro Kondoh; Isao Oze; Kyoko Kato; Toshiki Masuishi; Kazunori Honda; Yukiya Narita; Hiroya Taniguchi; Masashi Ando; Tsutomu Tanaka; Masahiro Tajika; Kei Muro
    Advances in therapy 37 6 2853 - 2864 2020年06月 
    INTRODUCTION: In patients with advanced gastric cancer refractory to chemotherapy, the treatment options are limited. Via this phase II study, we aimed to assess the efficacy and safety of oxaliplatin in combination with 5-fluorouracil and l-leucovorin (modified FOLFOX6). METHODS: Patients who had histologically confirmed metastatic gastric cancer refractory to ≥ two previous chemotherapy regimens were included. The primary endpoint was the overall response rate (ORR) by an independent central review. According to an assumption of a threshold ORR of 10% and expected ORR of 25%, with α = 0.05 and β = 0.20, at least 33 patients were required. The secondary endpoints included overall survival (OS), progression-free survival (PFS), quality of life measured by EQ-5D, and safety. RESULTS: Among the 35 enrolled patients, 33 were included in the primary analysis. All patients previously received fluoropyrimidines, cisplatin, and taxanes, and 24 (73%) were pretreated with irinotecan. The confirmed ORR was 27% [95% confidence interval (CI) 13-46]. The median PFS and OS were 2.2 (95% CI 1.2-3.2) and 5.6 (95% CI 4.1-7.0) months, respectively. In the multivariate analyses, immunotherapy within 90 days and a Glasgow Prognostic Score of 0 were associated with better treatment outcomes. The most common grade ≥ 3 adverse event was neutropenia (36%), and no febrile neutropenia was observed. The median EQ-5D scores did not change from baseline at 2, 4, and 8 weeks (p value = 0.38, 0.79, and 0.98, respectively). CONCLUSION: Modified FOLFOX6 (mFOLFOX6) showed substantial activity and acceptable toxicity for chemotherapy-refractory advanced gastric cancer. TRIAL REGISTRATION: UMIN Clinical Trial Registry (UMIN000016416).
  • Seiichiro Mitani; Ken Kato; Hiroyuki Daiko; Isao Nozaki; Takashi Kojima; Masahiko Yano; Satoru Nakagawa; Masaki Ueno; Masaya Watanabe; Shigeru Tsunoda; Tetsuya Abe; Shigenori Kadowaki; Tomohiro Kadota; Haruhiko Fukuda; Ryunosuke Machida; Yuko Kitagawa
    JOURNAL OF CLINICAL ONCOLOGY 38 15 2020年05月
  • Sadayuki Kawai; Naoki Fukuda; Shun Yamamoto; Seiichiro Mitani; Katsuhiro Omae; Takeru Wakatsuki; Ken Kato; Shigenori Kadowaki; Daisuke Takahari; Narikazu Boku; Kei Muro; Nozomu Machida
    BMC cancer 20 1 338 - 338 2020年04月 
    BACKGROUND: Ramucirumab monotherapy as a second-line treatment for advanced gastric cancer (AGC) prolongs survival compared to the best supportive care. However, in clinical practice, ramucirumab monotherapy is sometimes used as third- or later-line treatment for AGC refractory to fluoropyrimidine and taxanes. This study evaluated the efficacy and safety of salvage-line ramucirumab monotherapy for treating AGC. METHODS: The subjects of this retrospective study were advanced gastric or gastro-esophageal junction adenocarcinoma patients who received ramucirumab monotherapy after failure of 2 or more prior regimens containing fluoropyrimidine and taxanes but not ramucirumab. RESULTS: From June 2015 to April 2017, 51 patients were enrolled. The median progression-free survival (PFS) and overall survival (OS) were 1.8 (95% confidence interval [CI] = 1.6-2.2) and 5.1 (95% CI = 4.0-6.8) months, respectively. The objective response and disease control rates were 2 and 17%, respectively. Grade 3 adverse events (AEs; e.g., anemia, fatigue, hypertension, proteinuria, intestinal bleeding) occurred in seven (13%) patients, but no grade 4 AEs and treatment-related deaths were observed. A neutrophil-lymphocyte ratio (NLR) of < 2.5 and previous gastrectomy were associated with better PFS. CONCLUSIONS: Salvage-line ramucirumab monotherapy has acceptable toxicity and comparable efficacy to second-line treatment; therefore, we consider physicians might choose this therapy as a salvage-line treatment option for AGC refractory to the standard therapies.
  • 三谷 誠一郎; 川上 尚人; 中川 和彦
    臨床消化器内科 35 5 495 - 500 (株)日本メディカルセンター 2020年04月 
    <文献概要>免疫チェックポイント阻害薬単剤の有効性は限定的であり,併用療法により,その有効性を高める試みが進んでいる.多くの併用療法が臨床試験において検討されている段階である.その代表的なものは,殺細胞性抗がん剤との併用,免疫チェックポイント阻害薬同士の併用であり,加えて,分子標的治療薬との併用も検討されている.治療開発が先行する他がん種の現況も紹介しつつ,消化器がんに対する免疫チェックポイント阻害薬と他剤との併用について解説する.
  • Kyoko Kato; Yukiya Narita; Seiichiro Mitani; Kazunori Honda; Toshiki Masuishi; Hiroya Taniguchi; Shigenori Kadowaki; Takashi Ura; Masashi Ando; Masahiro Tajika; Kei Muro
    Anticancer research 40 4 2247 - 2255 2020年04月 
    BACKGROUND/AIM: The efficacy of treatment using the anti-programmed cell death-1 (anti-PD-1) antibody for metastatic gastric cancer (mGC) has been established previously. Exploratory analyses in various types of tumours suggest that prior exposure to immune checkpoint inhibitors can enhance the efficacy of subsequent cytotoxic chemotherapy (CTx). Our aim is to evaluate the efficacy and safety of CTx for mGC after progression on anti-PD-(ligand) 1 [anti-PD-(L)1] antibody. PATIENTS AND METHODS: We retrospectively evaluated patients with mGC who underwent CTx. The patients received CTx after progression on anti-PD-(L)1 antibody (cohort A) or as a third-line treatment without prior exposure to anti-PD-(L)1 antibody (cohort B). We evaluated: i) clinical characteristics, ii) efficacies, iii) prognoses, and iv) adverse events (AEs). RESULTS: In cohorts A and B, 16 and 68 patients fulfilled the criteria, respectively. In the univariate analysis, the overall response rate was significantly higher in cohort A compared to cohort B (31% vs. 10%, respectively; Odds Ratio:3.96, 95% Confidence Interval:1.06-14.8, p=0.040). The multivariate analysis showed a similar trend. Immune-related AEs did not worsen and were manageable, while new immune-related AEs were not observed. CONCLUSION: CTx after progression on anti-PD-(L)1 antibody demonstrated a favourable efficacy in intensively treated patients with mGC.
  • Seiichiro Mitani; Hisato Kawakami
    Cancers 12 2 2020年02月 
    Trastuzumab, a monoclonal antibody to human epidermal growth factor receptor 2 (HER2), has improved survival in patients with HER2-positive advanced gastric or gastroesophageal junction cancer (AGC). The inevitable development of resistance to trastuzumab remains a problem, however, with several treatment strategies that have proven effective in breast cancer having failed to show clinical benefit in AGC. In this review, we summarize the mechanisms underlying resistance to HER2-targeted therapy and outline past and current challenges in the treatment of HER2-positive AGC refractory to trastuzumab. We further describe novel agents such as HER2 antibody-drug conjugates that are under development and have shown promising antitumor activity in early studies.
  • 消化器がん薬物療法up to date 切除不能進行再発胃癌に対するニボルマブ単独療法の臨床的予後予測因子の検討
    黒崎 隆; 川上 尚人; 三谷 誠一郎; 中川 和彦
    日本消化器病学会近畿支部例会プログラム・抄録集 112回 71 - 71 日本消化器病学会-近畿支部 2020年02月
  • irAE大腸炎を契機にICIの関与が疑われたStevens-Johnson症候群の1例
    黒崎 隆; 川上 尚人; 文田 壮一; 三谷 誠一郎; 中川 和彦
    日本内科学会雑誌 109 Suppl. 260 - 260 (一社)日本内科学会 2020年02月
  • TAKASHI KUROSAKI; HISATO KAWAKAMI; SEIICHIRO MITANI; RYOHEI KAWABATA; TAKAYUKI TAKAHAMA; YOSHIKANE NONAGASE; SOICHI FUMITA; TOMOHIRO OZAKI; YASUTAKA CHIBA; TAKAO TAMURA; KAZUHIKO NAKAGAWA
    In Vivo 34 4 1921 - 1929 2020年
  • Seiichiro Mitani; Shigenori Kadowaki; Isao Oze; Toshiki Masuishi; Yukiya Narita; Hideaki Bando; Sachiyo Oonishi; Yutaka Hirayama; Tsutomu Tanaka; Masahiro Tajika; Yutaro Koide; Takeshi Kodaira; Tetsuya Abe; Kei Muro
    Cancer medicine 9 1 394 - 400 2020年01月 
    BACKGROUND: Esophageal cancer is associated with synchronous or metachronous cancer at other primary sites. However, few studies have evaluated the second malignancies after the treatment of esophageal cancer. The present study aimed to clarify the frequency of and risk factors for the second malignancies after definitive therapy for esophageal cancer. PATIENTS AND METHODS: We included patients with esophageal cancer who received definitive therapy between 2000 and 2010. Exclusion criteria were synchronous cancer or a past history of cancer. Standardized incidence rate (SIR) was calculated using age- and sex-specific incidence rates from the cancer registry data. To conduct risk analyses, we used the competing risk regression model, which defined death and the development of second malignancies as competing risks. RESULTS: A total of 758 patients were included, with 131 second malignancies occurring in 106 patients (14%), over a median follow-up of 3.7 years. Cumulative incidences of second malignancies after 3, 5, and 8 years were 4.0%, 7.6%, and 13.8%, respectively. The risk of second malignancy was significantly elevated [SIR = 1.83, 95% confidence interval (CI): 1.50-2.22]. The most common sites of primary tumor were the head and neck (20%), followed by the lung (17%), stomach (16%), colon and rectum (11%), and urinary tract (9%). Risk analyses revealed that age ≥ 65 years [subdistribution hazard ratio (sHR): 1.51, 95% CI: 1.01-2.24, vs age < 65] and clinical stages 0-I (sHR: 2.48, 95% CI: 1.46-4.22, vs stage III and IV) and II (sHR: 2.10, 95% CI: 1.23-3.58, vs stage III and IV) were significantly associated with second malignancies. CONCLUSIONS: Compared with the general population, an increased incidence of second malignancies was observed in the patients with esophageal cancer in the present study even after definitive treatment. Careful follow-up is required, especially in patients at a higher risk of second malignancies.
  • Yasuyuki Hosono; Toshiki Masuishi; Seiichiro Mitani; Rui Yamaguchi; Seiichi Kato; Takayuki Yoshino; Hiromichi Ebi
    JCO Precision Oncology 3 1 - 5 2019年12月 [査読有り]
  • Seiichiro Mitani; Shigenori Kadowaki; Hiroko Hasegawa; Takeru Wakatsuki; Hiroki Hara; Masahiro Tajika; Kazuhiro Nishikawa; Motohiro Hirao; Daisuke Takahari; Keisho Chin; Kei Muro
    International journal of clinical oncology 24 10 1197 - 1203 2019年10月 
    BACKGROUND: S-1 monotherapy is one of the standard adjuvant treatments for patients with stage II and III gastric cancers. Early recurrence after S-1 adjuvant therapy has a poor prognosis. This study aimed to clarify the treatment outcomes of systemic chemotherapy and explore encouraging regimens. METHODS: This was a multicenter retrospective study. Among gastric cancer patients who underwent curative gastrectomy followed by adjuvant S-1 monotherapy, patients who experienced a recurrence while receiving adjuvant therapy or within 6 months after completion and started systemic chemotherapy at four institutions between 2005 and 2015 were eligible. RESULTS: A total of 112 patients were included. The main treatment regimens were weekly paclitaxel (n = 38, 34%), irinotecan plus cisplatin (n = 31, 28%), capecitabine plus cisplatin (n = 7, 6%), and irinotecan monotherapy (n = 6, 5%). For all patients, median progression-free survival and overall survival were 3.7 and 11.4 months, respectively. Among 77 patients with measurable lesions, the overall response and disease control rates were 24.7% and 62.3%, respectively. Multivariate analyses for overall survival showed that Eastern Cooperative Oncology Group performance status 2 [hazard ratio (HR) 3.71; 95% confidence interval (CI) 1.78-7.73] and undifferentiated histological type (HR 2.04; 95% CI 1.35-3.44) were independent prognostic factors, and treatment regimens were not prognostic. Exploratory comparisons did not show statistically significant differences between treatment regimens. CONCLUSIONS: This study of the largest number of patients with early recurrence after S-1 adjuvant monotherapy demonstrated that the prognosis for patients treated by all regimens was similar and poor.
  • Jiro Watari; Seiichiro Mitani; Chiyomi Ito; Katsuyuki Tozawa; Toshihiko Tomita; Tadayuki Oshima; Hirokazu Fukui; Shigenori Kadowaki; Seiji Natsume; Yoshiki Senda; Masahiro Tajika; Kazuo Hara; Yasushi Yatabe; Yasuhiro Shimizu; Kei Muro; Takeshi Morimoto; Seiichi Hirota; Kiron M Das; Hiroto Miwa
    Scientific reports 9 1 10526 - 10526 2019年07月 
    Non-ampullary duodenal adenocarcinoma (NADC) is extremely rare. Little is known about its clinicopathological and molecular features or its management. Herein we retrospectively analyzed the cases of 32 NADC patients, focusing on microsatellite instability (MSI), genetic mutations, CpG island methylator phenotype (CIMP), and immunostaining including mucin phenotype and PD-L1 expression. The incidence of MSI, KRAS/BRAF/GNAS mutations and CIMP was 51.6%, 34.4%/3.1%/6.5% and 28.1%, respectively. PD-L1 expression was seen in 34.4% of patients. No significant associations between clinicopathological features and KRAS/BRAF/GNAS genetic mutations or CIMP were found. Histologically non-well-differentiated-type NADCs and those in the 1st portion of the duodenum were significantly associated with later stages (stages III-IV) (P = 0.006 and P = 0.003, respectively). Gastric-phenotype NADCs were frequently observed in the 1st portion and in late-stage patients; their cancer cells more frequently expressed PD-L1. Histologically, the non-well-differentiated type was an independent predictor of PD-L1 expression in cancer cells (OR 25.05, P = 0.04) and immune cells (OR 44.14, P = 0.02). Only late-stage disease (HR 12.23, P = 0.01) was a prognostic factor for worse overall survival in a Cox proportional hazards regression model. Our observation of high proportions of MSI and PD-L1 expression may prompt the consideration of immune checkpoint inhibitors as a new treatment option for NADCs.
  • Kazunori Honda; Bishal Gyawali; Masashi Ando; Ryosuke Kumanishi; Kyoko Kato; Keiji Sugiyama; Seiichiro Mitani; Toshiki Masuishi; Yukiya Narita; Hideaki Bando; Hiroya Taniguchi; Shigenori Kadowaki; Takashi Ura; Kei Muro
    Journal of global oncology 5 1 - 8 2019年05月 
    PURPOSE: We previously reported on the pilot study assessing the feasibility of using the Japanese translation of the Comprehensive Score for Financial Toxicity (COST) tool to measure financial toxicity (FT) among Japanese patients with cancer. In this study, we report the results of the prospective survey assessing FT in Japanese patients with cancer using the same tool. PATIENTS AND METHODS: Eligible patients were receiving chemotherapy for a solid tumor for at least 2 months. In addition to the COST survey, socioeconomic characteristics were collected by using a questionnaire and medical records. RESULTS: Of the 191 patients approached, 156 (82%) responded to the questionnaire. Primary tumor sites were colorectal (n = 77; 49%), gastric (n = 39; 25%), esophageal (n = 16; 10%), thyroid (n = 9; 6%), head and neck (n = 4; 3%), and other (n = 11; 7%). Median COST score was 21 (range, 0 to 41; mean ± standard deviation, 12.1 ± 8.45), with lower COST scores indicating more severe FT. On multivariable analyses using linear regression, older age (β, 0.15 per year; 95% CI, 0.02 to 0.28; P = .02) and higher household savings (β, 8.24 per \15 million; 95% CI, 4.06 to 12.42; P < .001) were positively associated with COST score; nonregular employment (β, -5.37; 95% CI, -10.16 to -0.57; P = .03), retirement because of cancer (β, -5.42; 95% CI, -8.62 to -1.37; P = .009), and use of strategies to cope with the cost of cancer care (β, -5.09; 95% CI, -7.87 to -2.30; P < .001) were negatively associated with COST score. CONCLUSION: Using the Japanese version of the COST tool, we identified various factors associated with FT in Japanese patients with cancer. These findings will have important implications for cancer policy planning in Japan.
  • Kei Muro; Taroh Satoh; Kensei Yamaguchi; Atsuo Takashima; Shigenori Kadowaki; Daisuke Sakai; Takashi Ichimura; Seiichiro Mitani; Toshihiro Kudo; Keisho Chin; Shigehisa Kitano; Pankaj Bhargava; Marianna Zavodovskaya; JieJane Liu; Masato Fukui; Narikazu Boku
    JOURNAL OF CLINICAL ONCOLOGY 37 4 2019年02月
  • Kensei Yamaguchi; Taroh Satoh; Kei Muro; Atsuo Takashima; Takashi Ichimura; Daisuke Sakai; Shigenori Kadowaki; Keisho Chin; Toshihiro Kudo; Seiichiro Mitani; Shigehisa Kitano; Pankaj Bhargava; Marianna Zavodovskaya; JieJane Liu; Masato Fukui; Narikazu Boku
    JOURNAL OF CLINICAL ONCOLOGY 37 4 2019年02月
  • Naoya Hashimoto; Seiichiro Mitani; Hiroya Taniguchi; Yukiya Narita; Kyoko Kato; Toshiki Masuishi; Shigenori Kadowaki; Sachiyo Onishi; Masahiro Tajika; Shinji Takahashi; Kazuhiro Shimomura; Chihoko Takahata; Eri Hotta; Makiko Kobara; Kei Muro
    The oncologist 24 2 159-e66  2019年02月 
    LESSONS LEARNED: A shortened infusion of ramucirumab (from 60 to 20 minutes) was safe and feasible without infusion-related reactions.Twenty-minute infusions of ramucirumab can be an option for patients with no infusion-related reactions during the first 60-minute treatment. BACKGROUND: Ramucirumab is usually administered over 60 minutes, during which it is unlikely to cause infusion-related reactions (IRRs). This prospective study evaluated the safety of a shortened infusion of ramucirumab. METHODS: Patients who received their first dose of ramucirumab in a 60-minute infusion without developing IRRs were eligible and received their second ramucirumab dose for 20 minutes. The primary study endpoint was incidence of IRR during the first short-term infusion, and the secondary endpoints were incidence of IRR at any time and adverse events other than IRR. RESULTS: Of the 40 patients enrolled (median age, 68.5 years), 20 (55%) were male, 27 (67.5%) had stage IV gastric cancer, 25 (62.5%) received ramucirumab in combination with taxane-based chemotherapy, and 24 (60%) received only a single administration of ramucirumab prior to their enrollment. Notably, no IRR was observed during the first short-term infusion (IRR rate, 0%; 95% confidence interval [CI], 0%-0.72%). Among the 149 short-term infusions performed, there were no instances of IRRs or unexpected adverse events related to the treatment (Table 1). CONCLUSION: For patients without development of IRRs upon the first ramucirumab administration, shortening infusion time (from 60 to 20 minutes) is safe and feasible.
  • Kaori Hayashi; Seiichiro Mitani; Hiroya Taniguchi; Hirofumi Yasui; Kei Muro; Keita Mori; Takuji Gotoda; Kentaro Yamazaki
    Oncology 96 3 132 - 139 2019年 
    OBJECTIVE: Anti-epithelial growth factor receptor (EGFR) antibodies cetuximab (Cmab) and panitumumab (Pmab) have shown survival benefit for metastatic colorectal cancer (mCRC) patients. This study aimed to compare Pmab and Cmab according to the interval between bevacizumab discontinuation and anti-EGFR antibody initiation (bevacizumab-free interval; BFI). METHODS: We retrospectively evaluated mCRC patients who received Cmab or Pmab in combination with irinotecan at two institutions. Inclusion criteria were histologically confirmed mCRC, with KRAS exon 2 wild-type tumor, refractory or intolerant to fluoropyrimidines, oxali platin, and irinotecan. RESULTS: One-hundred-seventy-eight patients fulfilled the eligibility criteria. Among them, there was no significant difference in overall survival (OS) and progression-free survival (PFS) between the Pmab (n = 44) and Cmab groups (n = 134). Of 132 patients with BFI < 6 months, the median OS was 13.3 and 11.5 months in the Pmab (n = 39) and Cmab (n = 93) groups, respectively (p = 0.043). The median PFS was 5.8 and 4.9 months in the Pmab and Cmab groups, respectively (p = 0.055). Multivariate analysis for OS confirmed the superiority of Pmab. CONCLUSION: Pmab showed more favorable outcomes in patients treated with bevacizumab within the last 6 months. The interval between prior bevacizumab and subsequent anti-EGFR therapy may be useful for determining the optimal anti-EGFR therapy.
  • Seiichiro Mitani; Hiroya Taniguchi; Keiji Sugiyama; Toshiki Masuishi; Kazunori Honda; Yukiya Narita; Shigenori Kadowaki; Takashi Ura; Masashi Ando; Masahiro Tajika; Yasushi Yatabe; Kei Muro
    Therapeutic advances in medical oncology 11 1758835918820298 - 1758835918820298 2019年 
    Background: BRAF (v-raf murine sarcoma viral oncogene homolog B1) V600E mutant colorectal cancer is associated with short survival. Recently, clinical trials have been conducted to improve outcomes of second or later lines of chemotherapy. However, there is a paucity of reference data pertaining to outcomes of second-line chemotherapy and prognostic factors that are relevant only to BRAF mutant patients. Patients and methods: We retrospectively reviewed metastatic colorectal cancer patients with BRAF V600E mutation who underwent second-line chemotherapy between January 2007 and March 2017. We evaluated treatment outcomes and performed prognostic analyses. Results: A total of 52 patients were included. The median progression-free survival and overall survival (OS) were 2.5 [95% confidence interval (CI) = 1.91-4.11] and 6.5 (95% CI = 4.30-9.63) months, respectively. Overall response and disease control rates were 7% and 48%, respectively. All the regimens which elicited a partial response included BRAF inhibitors in combination with anti-epidermal growth factor receptor (EGFR) antibodies. Therefore, the overall response was 0% after exclusion of patients treated with study drugs. Multivariate analysis for OS revealed that the Glasgow Prognostic Score (GPS), elevated lactate dehydrogenase, and poor performance status were independent prognostic factors. In particular, survival curves according to the GPS stratified the patients into distinct risk groups. The median OSs in patients with GPS of 0, 1, and 2 were 9.9, 5.0, and 1.9 months, respectively. Conclusions: Outcomes of second-line chemotherapy for metastatic colorectal cancer patients with BRAF V600E mutation were extremely poor. GPS may be useful in future clinical trials.
  • Toshiki Masuishi; Hiroya Taniguchi; Tetsuya Eto; Azusa Komori; Seiichiro Mitani; Hiroko Hasegawa; Yukiya Narita; Makoto Ishihara; Tsutomu Tanaka; Shigenori Kadowaki; Takashi Ura; Masashi Ando; Masahiro Tajika; Motoo Nomura; Yozo Sato; Hideyuki Mishima; Kei Muro
    Anticancer research 38 11 6501 - 6506 2018年11月 
    BACKGROUND/AIM: Anti-EGFR antibodies or bevacizumab comprise first-line treatment for patients with RAS wild-type colorectal liver metastases (CLM). Which marker better predicts efficacy, early tumor shrinkage or morphologic response, still remains unclear. PATIENTS AND METHODS: We retrospectively evaluated 155 patients with KRAS exon 2 wild-type CLM treated with bevacizumab (BEV group) or anti-EGFR antibodies (EGFR group). Three radiologists independently assessed early tumor shrinkage (ETS) and early optimal morphologic response (EOMR) from baseline and first follow-up CT scan. RESULTS: Patients with ETS had longer progression-free survival (PFS) than those without ETS [hazard ratio (HR)=0.69] and ETS tended to be observed in the EGFR group, while patients with EOMR had longer PFS than those without EOMR (HR=0.64) and EOMR tended to be observed in the BEV group. CONCLUSION: Among patients with KRAS exon 2 wild-type CLM, EOMR and ETS may predict better PFS, especially in patients treated with bevacizumab and anti-EGFR antibodies, respectively.
  • Keiji Sugiyama; Yukiya Narita; Seiichiro Mitani; Kazunori Honda; Toshiki Masuishi; Hiroya Taniguchi; Shigenori Kadowaki; Takashi Ura; Masashi Ando; Masahiro Tajika; Kei Muro
    Anticancer research 38 10 5859 - 5866 2018年10月 
    AIM: To determine the association between sarcopenia and prognosis in patients with metastatic gastric cancer (mGC) receiving chemotherapy. PATIENTS AND METHODS: Our study retrospectively evaluated 231 consecutive Japanese patients with mGC who commenced first-line chemotherapy at our Institution between January 2013 and December 2015. Muscle loss during chemotherapy was defined as a ≥10% reduction in the skeletal muscle index and was evaluated for its association with time to treatment failure (TTF) and overall survival (OS). RESULTS: Of 118 patients, 89% had baseline sarcopenia and 31% developed muscle loss. Muscle loss was significantly associated with shorter TTF and OS and was an independent prognostic factor for both these parameters; poor performance status and poorer differentiation on histology were also significant predictors of shorter OS. However, muscle loss was not significantly associated with increased grade 3 or higher toxicities. CONCLUSION: Muscle loss during chemotherapy negatively affected survival among patients with mGC.
  • T. Masuishi; H. Taniguchi; K. Sugiyama; K. Kato; S. Mitani; K. Honda; Y. Narita; S. Kadowaki; T. Ura; M. Ando; K. Muro
    Annals of Oncology 29 5 1330 - 1331 2018年05月
  • Kazunori Honda; Bishal Gyawali; Masashi Ando; Keiji Sugiyama; Seiichiro Mitani; Toshiki Masuishi; Yukiya Narita; Hiroya Taniguchi; Shigenori Kadowaki; Takashi Ura; Kei Muro
    Ecancermedicalscience 12 847 - 847 2018年 
    Background: Financial toxicity (FT) has a negative impact on the quality of life and survival of patients with cancer. The comprehensive score for FT (COST) questionnaire is a tool to measure FT which has already been validated in patients with cancer in the United States. However, the feasibility and validity of assessing FT using the COST questionnaire have not been established in non-US healthcare settings, including that in Japan. Methods: This is a prospective pilot survey to ascertain the feasibility of using the COST questionnaire to evaluate FT in Japanese patients with advanced solid cancer who had been receiving chemotherapy for at least 2 months. The COST questionnaire was translated into Japanese using Functional Assessment of Chronic Illness Therapy methodology. Results: Of the 12 patients approached, 11 (92%) responded to the questionnaire. The median COST score was 22 (range, 6-29; mean ± SD, 20.18 ± 8.17). Five (45%) and two (18%) patients suffered grade 1 (COST score 14-25) and grade 2 (COST score 1-13) FT, respectively. The COST measure demonstrated good internal consistency with a Cronbach α of 0.87. Conclusions: The COST measure demonstrated good feasibility in measuring FT in the Japanese healthcare setting. Despite the existing universal health insurance system and ceiling amount for high-cost medical expenses, some Japanese patients experienced meaningful FT during chemotherapy. A prospective study is already underway to confirm the preliminary results (UMIN: 000025043).
  • Toshiki Masuishi; Shigenori Kadowaki; Mayumi Kondo; Azusa Komori; Keiji Sugiyama; Seiichiro Mitani; Kazunori Honda; Yukiya Narita; Hiroya Taniguchi; Takashi Ura; Masashi Ando; Hideyuki Mishima; Kei Muro
    Anticancer research 37 12 7037 - 7042 2017年12月 
    BACKGROUND/AIM: Severe peritoneal metastasis (PM) from advanced gastric cancer (AGC) causes massive ascites and inadequate oral intake. Because patients with severe PM are often not included in clinical trials, little is known regarding the efficacy and safety of oxaliplatin with l-leucovorin and bolus/continuous infusion of 5-fluorouracil (FOLFOX) for them. PATIENTS AND METHODS: We retrospectively studied AGC patients with massive ascites and/or inadequate oral intake due to severe PM treated with FOLFOX as the first-line treatment. RESULTS: Only 39 (10%) of 378 AGC patients had severe PM; 10 received FOLFOX. The median progression-free and overall survivals were 7.5 and 13.2 months, respectively. Ascites decreased in seven of nine patients with ascites, and oral intake improved in four of seven patients with an inadequate oral intake. Common grade 3-4 adverse events included neutropenia and anemia. CONCLUSION: This study suggests that FOLFOX is effective and manageable for AGC patients with severe PM.
  • フッ化ピリミジン・タキサン不応・不耐胃癌に対する3次治療以降のRamucirumab単剤療法
    山本 駿; 河合 卓幸; 大前 勝弘; 福田 直樹; 三谷 誠一郎; 若槻 尊; 加藤 健; 門脇 重憲; 高張 大亮; 朴 成和; 室 圭; 町田 望
    日本癌治療学会学術集会抄録集 55回 P170 - 5 (一社)日本癌治療学会 2017年10月
  • Kazunori Honda; Masashi Ando; Keiji Sugiyama; Seiichiro Mitani; Toshiki Masuishi; Yukiya Narita; Hiroya Taniguchi; Shigenori Kadowaki; Takashi Ura; Kei Muro
    Case Reports in Oncology 10 3 863 - 870 2017年09月 
    Angiosarcoma of the heart is an uncommon soft tissue sarcoma. A few cases of disseminated intravascular coagulation (DIC) associated with angiosarcoma occurring in various organs, but not the heart, have been reported. Although taxane is commonly used in the treatment of metastatic angiosarcoma, data on the efficacy of nab-paclitaxel for angiosarcoma are limited. Here, we report probably the first case of a patient with primary cardiac angiosarcoma with coexisting DIC who was successfully treated with nab-paclitaxel. A 62-year-old female with chief complaints of nausea and shortness of breath was diagnosed as having cardiac angiosarcoma with liver metastases. Four months after the resection of her primary tumor, the hepatic metastatic lesions progressed rapidly accompanied by new metastatic lesions in the right iliac bone and signs of DIC. She received nab-paclitaxel as first-line chemotherapy. A response of stable disease was achieved after 2 treatment cycles and DIC was successfully controlled for at least 4 months. This report suggests potential utility of nab-paclitaxel for angiosarcoma complicated with DIC. We also review the literature for all cases of angiosarcoma with DIC reported so far.
  • Seiichiro Mitani; Shigenori Kadowaki; Azusa Komori; Keiji Sugiyama; Yukiya Narita; Hiroya Taniguchi; Takashi Ura; Masashi Ando; Yozo Sato; Hidekazu Yamaura; Yoshitaka Inaba; Makoto Ishihara; Tsutomu Tanaka; Masahiro Tajika; Kei Muro
    Medicine 96 22 e6874  2017年06月 
    Acute hyperammonemic encephalopathy induced by fluoropyrimidines (FPs) is a rare complication. Its pathophysiology remains unclear, especially given the currently used regimens, including intermediate-doses of 5-fluorouracil (5-FU) or oral FP agents. We aimed to characterize the clinical manifestations in cancer patients who developed hyperammonemic encephalopathy after receiving FP-based chemotherapy.We retrospectively reviewed 1786 patients with gastrointestinal or primary-unknown cancer who received FP-based regimens between 2007 and 2012. Eleven patients (0.6%) developed acute hyperammonemic encephalopathy. The incidence according to the administered anticancer drugs were as follows: 5-FU (8 of 1176, 0.7%), S-1 (1 of 679, 0.1%), capecitabine (2 of 225, 0.9%), and tegafur-uracil (UFT) (0 of 39, 0%). Ten patients (90.9%) had at least 1 aggravating factor, including infection, dehydration, constipation, renal dysfunction, and muscle loss. All the 10 patients met the definition of sarcopenia. Median time to the onset of hyperammonemic encephalopathy in the cycle was 3 days (range: 2-21). Three patients (27.3%) developed encephalopathy during the first cycle of the regimen and the remaining 8 patients during the second or more cycles. Seven patients (63.6%) had received at least 1 other FP-containing regimen before without episodes of encephalopathy.All patients recovered soon after immediate discontinuation of chemotherapy and supportive therapies, such as hydration, infusion of branched-chain amino acids, and oral lactulose intake, with a median time to recovery of 2 days (range: <1-7). Four patients (36.4%) received FP-based regimens after improvement of symptoms; 3 patients were successfully managed with dose reduction, and 1 patient, who had developed encephalopathy due to S-1 monotherapy, received modified FOLFOX-6 therapy without encephalopathy later.FP-associated acute hyperammonemic encephalopathy is extremely rare, but a possible event at any time and even during the administration of oral FP agents. Particular attention is warranted when giving FP-based therapy for patients with aggravating factors, such as sarcopenia. This complication can be properly managed with early detection.
  • Yukiya Narita; Keiji Sugiyama; Seiichiro Mitani; Kazunori Honda; Toshiki Masuishi; Hiroya Taniguchi; Shigenori Kadowaki; Takashi Ura; Masashi Ando; Masahiro Tajika; Kei Muro
    JOURNAL OF CLINICAL ONCOLOGY 35 2017年05月
  • Katsuyuki Murai; Toshiki Masuishi; Hiroya Taniguchi; Satoshi Hamauchi; Keiji Sugiyama; Takahiro Tsushima; Seiichiro Mitani; Akiko Todaka; Kazunori Honda; Tomoya Yokota; Yukiya Narita; Nozomu Machida; Shigenori Kadowaki; Akira Fukutomi; Takashi Ura; Yusuke Onozawa; Masashi Ando; Hirofumi Yasui; Kei Muro; Kentaro Yamazaki
    JOURNAL OF CLINICAL ONCOLOGY 35 4 2017年02月
  • Keiji Sugiyama; Yukiya Narita; Seiichiro Mitani; Kazunori Honda; Toshiki Masuishi; Hiroya Taniguchi; Shigenori Kadowaki; Takashi Ura; Masashi Ando; Masahiro Tajika; Kei Muro
    JOURNAL OF CLINICAL ONCOLOGY 35 4 2017年02月
  • Hiroko Hasegawa; Hiroya Taniguchi; Seiichiro Mitani; Toshiki Masuishi; Azusa Komori; Yukiya Narita; Shigenori Kadowaki; Takashi Ura; Masashi Ando; Yasushi Yatabe; Kei Muro
    ONCOLOGY 92 4 205 - 212 2017年 [査読有り]
     
    Objective: Anti-epidermal growth factor receptor (EGFR) antibodies and bevacizumab are commonly used, sequentially, as palliative chemotherapies for patients with metastatic colorectal cancer. However, little is known about the efficacy of second-line treatments containing bevacizumab after first-line treatment with an anti-EGFR antibody. Methods: We retrospectively reviewed 128 patients who received second -line bevacizumab-containing chemotherapy and evaluated the effect of prior use of anti-EGFR antibody on the efficacy of the second-line treatment. Results: As first-line treatments, 35 of these patients received only cytotoxic chemotherapy (cohort A), 58 received bevacizumab-containing chemotherapy (cohort B), and 35 received anti-EGFR-containing chemotherapy (cohort C). The median progression free survival (PFS) with the second-line bevacizumab-containing therapy was 8.3 months in cohort C, 6.9 months in cohort A (hazard ratio [1-1R], 1.43; 95% confidence interval [CI], 0.83-2.51), and 5.6 months in cohort B (HR, 1.95; 95% CI, 1.18-3.22). Multivariate analysis showed that PFS in cohort C was the same as that in cohort A, but better than that in cohort B. The overall response rate in cohort C (25.7%) was also similar to that in cohort A (20.0%), but better than that in cohort B (10.3%). Conclusions: Prior use of anti-EGFR antibody did not adversely affect the efficacy of subsequent bevacizumab-containing chemotherapy. (C) 2017 S. Ka rger AG, Basel
  • Seiichiro Mitani; Shigenori Kadowaki; Isao Oze; Hiroya Taniguchi; Takashi Ura; Masahiro Tajika; Chiyoko Makita; Takeshi Kodaira; Norihisa Uemura; Tetsuya Abe; Kei Muro
    ANNALS OF ONCOLOGY 27 2016年07月
  • Seiichiro Mitani; Shigenori Kadowaki; Hiroya Taniguchi; Hisanori Muto; Kei Muro
    Case Reports in Oncology 9 1 106 - 111 2016年02月 
    We present the first reported case of pseudocirrhosis arising after a dramatic response to chemotherapy in metastatic gastric cancer. A 74-year-old man was diagnosed with gastric adenocarcinoma having multiple liver metastases. His general condition was poor, with an Eastern Cooperative Oncology Group performance status of 3, inadequate oral intake, and jaundice (total bilirubin 2.8 mg/dl). Chemotherapy with oxaliplatin, L-leucovorin, and 5-fluorouracil (modified FOLFOX-6) was initiated. After four treatment cycles, he experienced a marked regression of liver metastases; however, he developed massive ascites with a lobular liver surface and segmental atrophy, which were consistent with pseudocirrhosis. Chemotherapy was continued along with ascites management. Thereafter, ascites disappeared, and a complete response of the metastatic lesions was achieved at 11 months after initial treatment. He had no evidence of disease progression at 30 months after initial chemotherapy. This report suggests clinicians should recognize this entity, even in gastric cancer metastatic to the liver.
  • Yukiya Narita; Hiroko Hasegawa; Azusa Komori; Seiichiro Mitani; Toshiki Masuishi; Hiroya Taniguchi; Shigenori Kadowaki; Takashi Ura; Masashi Ando; Seiji Ito; Yasushi Yatabe; Masahiro Tajika; Kei Muro
    JOURNAL OF CLINICAL ONCOLOGY 34 4 2016年02月

MISC

  • 佐藤 千尋; 三谷 誠一郎; 川上 尚人 がん分子標的治療 17 (2) 133 -138 2019年12月
  • 切除不能進行食道扁平上皮癌に対するmodified FOLFOX6療法の検討
    三谷 誠一郎; 門脇 重憲; 舛石 俊樹; 谷口 浩也; 宇良 敬; 安藤 正志; 田近 正洋; 古平 毅; 安部 哲也; 室 圭 日本食道学会学術集会プログラム・抄録集 72回 393 -393 2018年06月
  • 抗PD-(L)1抗体薬不応後の切除不能胃癌に対する化学療法の有効性(Efficacy of chemotherapy after progression on anti-PD-(L)1 antibody for metastatic gastric cancer)
    加藤 恭子; 成田 有季哉; 三谷 誠一郎; 本多 和典; 舛石 俊樹; 谷口 浩也; 門脇 重憲; 宇良 敬; 安藤 正志; 田近 正洋; 室 圭 日本胃癌学会総会記事 90回 485 -485 2018年03月
  • Naoki Fukuda; Sadayuki Kawai; Katsuhiro Omae; Seiichiro Mitani; Takeru Wakatsuki; Ken Kato; Shigenori Kadowaki; Daisuke Takahari; Narikazu Boku; Kei Muro; Nozomu Machida JOURNAL OF CLINICAL ONCOLOGY 36 (4) 2018年02月
  • 大腸がん化学療法の最前線 切除不能BRAF変異型大腸がんに対する治療戦略
    谷口 浩也; 三谷 誠一郎; 室 圭 日本消化管学会雑誌 2 (Suppl.) 199 -199 2018年02月
  • 抗PD-1/PD-L1抗体薬不応後の胃癌に対する殺細胞性抗がん剤の有効性と安全性
    加藤 恭子; 成田 有季哉; 岡野 裕子; 小島 勇貴; 三谷 誠一郎; 本多 和典; 舛石 俊樹; 谷口 浩也; 門脇 重憲; 宇良 敬; 安藤 正志; 田近 正洋; 室 圭 日本癌治療学会学術集会抄録集 55回 P169 -2 2017年10月
  • 競合リスクモデルを用いた食道癌根治治療後の他臓器癌発生リスクの検討
    三谷 誠一郎; 尾瀬 功; 門脇 重憲; 本多 和典; 舛石 俊樹; 成田 有季哉; 谷口 浩也; 宇良 敬; 安藤 正志; 田近 正洋; 牧田 智誉子; 古平 毅; 植村 則久; 安部 哲也; 室 圭 日本癌治療学会学術集会抄録集 55回 P128 -6 2017年10月
  • Y. Narita; E. Sasaki; Y. Yatabe; K. Kato; H. Okano; S. Mitani; K. Honda; T. Masuishi; H. Taniguchi; S. Kadowaki; T. Ura; M. Ando; M. Tajika; S. Ito; K. Muro ANNALS OF ONCOLOGY 28 2017年09月
  • S. Mitani; I. Oze; S. Kadowaki; T. Masuishi; Y. Narita; H. Taniguchi; T. Ura; M. Ando; M. Tajika; C. Makita; T. Kodaira; N. Uemura; T. Abe; K. Muro ANNALS OF ONCOLOGY 28 2017年09月
  • 大腸 分子標的治療薬 ベバシズマブ 一次治療dublet+bevacizumab療法はKRAS遺伝子型に関わらず大腸癌の予後を延長する
    舛石 俊樹; 谷口 浩也; 杉山 圭司; 三谷 誠一郎; 本多 和典; 成田 有季哉; 門脇 重憲; 宇良 敬; 安藤 正志; 田近 正洋; 室 圭 日本癌治療学会学術集会抄録集 54回 WS50 -1 2016年10月
  • 胃 化学療法 DIC合併進行胃癌に対する初回フッ化ピリミジン・プラチナ併用化学療法
    杉山 圭司; 成田 有季哉; 門脇 重憲; 三谷 誠一郎; 本多 和典; 舛石 俊樹; 谷口 浩也; 宇良 敬; 安藤 正志; 田近 正洋; 室 圭 日本癌治療学会学術集会抄録集 54回 WS103 -1 2016年10月
  • S. Mitani; S. Kadowaki; I. Oze; T. Masuishi; Y. Narita; H. Taniguchi; T. Ura; M. Ando; M. Tajika; C. Makita; T. Kodaira; N. Uemura; T. Abe; K. Muro ANNALS OF ONCOLOGY 27 2016年10月
  • Toshiki Masuishi; Hiroya Taniguchi; Satoshi Hamauchi; Azusa Komori; Yosuke Kito; Seiichiro Mitani; Hiroko Hasegawa; Yukiya Narita; Shigenori Kadowaki; Takashi Ura; Masashi Ando; Keita Mori; Masahiro Tajika; Hirofumi Yasui; Kei Muro; Kentaro Yamazaki JOURNAL OF CLINICAL ONCOLOGY 34 (4) 2016年02月
  • 大腸 大腸がん分子標的薬の最新情報 抗EGFR抗体薬の前治療は大腸癌の二次治療Bevacizumab併用療法の治療効果に影響するか?
    長谷川 裕子; 谷口 浩也; 三谷 誠一郎; 舛石 俊樹; 小森 梓; 成田 有季哉; 門脇 重徳; 宇良 敬; 安藤 正志; 田近 正洋; 室 圭 日本癌治療学会誌 50 (3) 1303 -1303 2015年09月
  • 大腸 大腸がん分子標的薬の最新情報 レゴラフェニブとTAS-102はどちらを先行すべきか? 静岡がん・愛知がん共同観察研究[3]
    舛石 俊樹; 谷口 浩也; 濱内 諭; 小森 梓; 木藤 陽介; 三谷 誠一郎; 長谷川 裕子; 成田 有季哉; 門脇 重憲; 宇良 敬; 安藤 正志; 田近 正洋; 安井 博史; 室 圭; 山崎 健太郎 日本癌治療学会誌 50 (3) 1306 -1306 2015年09月
  • 胃 胃がん腹膜播種へのアプローチ 当院における胃癌術後補助化学療法後の早期再発例に対する治療の現状
    三谷 誠一郎; 門脇 重憲; 舛石 俊樹; 成田 有季哉; 小森 梓; 長谷川 裕子; 谷口 浩也; 宇良 敬; 安藤 正志; 室 圭 日本癌治療学会誌 50 (3) 1397 -1397 2015年09月

その他のリンク

researchmap



Copyright © MEDIA FUSION Co.,Ltd. All rights reserved.